Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDT-3594 in Healthy Males and Parkinson's Disease Patients
NCT03068481Phase 1Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Feb 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of matsupexole in Parkinson's disease (PD) (5 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoints: Occurrence of adverse events at 15 days, Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: Cmax at 336 hours and 1 more. Started Feb 2017; status: completed.
02
Drugs
matsupexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03068481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068481.